Diabetes mellitus (DM) is a complex and multiple group
of disorders,
and understanding the molecular mechanisms is a key role in identifying
various markers involved in the diagnosis of the disease. Brucine
is derived from the seeds of Strychnos nux-vomica L. (Loganiaceae), which has been used in traditional medicine to
cure a variety of ailments, such as chronic rheumatism, nervous system
diseases, dyspepsia, gonorrhea, anemia, and bronchitis, and has analgesic,
anti-inflammatory, anti-oxidant, anti-snake venom, and anti-diabetic
properties. The anti-diabetic potential of brucine was studied utilizing in vitro, in silico, in vivo, and molecular methods, including streptozotocin-induced diabetic
rat models, α-glucosidase and α-amylase inhibitory assays,
and via Auto-DocVina software. Brucine exhibits binding affinities
of −5.0 to −10.1 Kcal/mol against chosen protein targets,
according to an in silico investigation. In vitro studies revealed that brucine inhibited the enzymes
α-amylase and α-glucosidase, and brucine (20 mg/kg) reduced
blood glucose levels, oral glucose tolerance overload, body weight,
glycosylated hemoglobin levels, total cholesterol, triglycerides,
low-density lipoprotein, alanine transaminase, aspartate aminotransferase,
total bilirubin, and alkaline phosphatase and elevated high-density
lipoprotein levels in in vivo studies. The brucine binding energy against certain protein targets ranges
from −5.0 to −10.1 Kcal/mol. It has anti-diabetic, anti-hyperlipidemic,
hepatoprotective, anti-oxidant, and anti-inflammatory properties,
which are mediated via inhibition of α-glucosidase and α-amylase.